Methotrexate Accord

Methotrexate, the active ingredient in Methotrexate Accord, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intra‑arterial, intramuscular and intravenous use. It is employed to treat rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, breast cancer and osteosarcoma in appropriate patients.

GNH USA supplies Methotrexate Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Methotrexate is used in autoimmune and oncologic disease pathways to modulate cell proliferation and immune activity. - Rheumatoid arthritis: reduces disease activity and joint inflammation. - Psoriasis: slows skin cell turnover and improves plaque lesions. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant lymphoblast proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control through cytotoxic effects on rapidly dividing cells. - Breast cancer: used as part of combination regimens to limit tumor growth. - Osteosarcoma: administered to suppress bone‑derived tumor cell replication.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Oral mucositis (mouth sores) - Transient elevation of liver enzymes - Decreased white blood cell count - Alopecia (hair thinning)

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis - Pulmonary toxicity, including interstitial pneumonitis - Life‑threatening bone marrow suppression - Acute renal failure - Severe infection due to immunosuppression

Prior to initiating therapy, several safety considerations should be addressed. - Baseline blood monitoring: obtain complete blood count and differential. - Liver function assessment: evaluate transaminases and bilirubin levels. - Renal function evaluation: check serum creatinine and clearance. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Breastfeeding restriction: not recommended for nursing mothers. - Concomitant drug review: avoid known hepatotoxic or nephrotoxic agents. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen, naproxen): increase methotrexate plasma levels and risk of toxicity. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: may enhance myelosuppression. - Phenytoin and carbamazepine: can reduce methotrexate effectiveness. - Proton pump inhibitors: may affect renal clearance of methotrexate.